JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herrick-Davis, K.
Right arrow Articles by Teitler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrick-Davis, K.
Right arrow Articles by Teitler, M.

Vol. 295, Issue 1, 226-232, October 2000

Inverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine2C Receptors1

Katharine Herrick-Davis, Ellinor Grinde and Milt Teitler

Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York

Clozapine is the prototype atypical antipsychotic drug, producing little or no extrapyramidal side effects, while improving negative symptoms of psychosis. Clozapine's high affinity for serotonin receptors has been hypothesized to confer the unique antipsychotic properties of this drug. Recently, we demonstrated that both typical and atypical antipsychotic drugs are inverse agonists at constitutively active 5-hydroxytryptamine2A (5-HT2A) receptors. To determine whether inverse agonist activity at 5-HT2C receptors plays a role in antipsychotic efficacy, typical and atypical antipsychotic drugs were tested for inhibition of basal inositol phosphate production in mammalian cells expressing rat or human 5-HT2C receptors. Atypical antipsychotic drugs (sertindole, clozapine, olanzapine, ziprasidone, risperidone, zotepine, tiospirone, fluperlapine, tenilapine) displayed potent inverse agonist activity at rat and human 5-HT2C receptors. Typical antipsychotic drugs (chlorpromazine, loxapine, thioridazine, prochlorperazine, perphenazine, mesoridazine, trifluperidol, fluphenazine, spiperone, haloperidol, pimozide, penfluridol, thiothixene) were devoid of inverse agonist activity, with the exception of loxapine. We review the evidence that loxapine has unique properties characteristic of both atypical and typical antipsychotic drugs. Several typical antipsychotic drugs (chlorpromazine, thioridazine, spiperone, thiothixene) displayed neutral antagonist activity by reversing clozapine inverse agonism. These data suggest that 5-HT2C inverse agonist activity is associated with atypical antipsychotic drugs with moderate to high affinity for 5-HT2C receptors, and imply that effects of atypical antipsychotic drugs on the 5-HT2C receptor may play a role in their unique clinical properties. These data also imply that dysfunction of brain 5-HT2C receptor systems may be one of the factors involved in the etiology of psychosis.

1 Supported by United State Public Health Services Grants MH-57019 (to K.H.-D.) and MH-56650 (to M.T.).

0022-3565/00/2951-0226$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
K. B. Fink and M. Gothert
5-HT Receptor Regulation of Neurotransmitter Release
Pharmacol. Rev., December 1, 2007; 59(4): 360 - 417.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. K. Singh, J. Shi, B. W. Zemaitaitis, and N. A. Muma
Olanzapine Increases RGS7 Protein Expression via Stimulation of the Janus Tyrosine Kinase-Signal Transducer and Activator of Transcription Signaling Cascade
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 133 - 140.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Wang, X. Sun, and W. Sadee
Different Effects of Opioid Antagonists on {micro}-, {delta}-, and {kappa}-Opioid Receptors with and without Agonist Pretreatment
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 544 - 552.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. A. Berg, S. Navailles, T. A. Sanchez, Y. M. Silva, M. D. Wood, U. Spampinato, and W. P. Clarke

J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 260 - 268.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-i. Miura, M. Fujino, H. Hanzawa, Y. Kiya, S. Imaizumi, Y. Matsuo, S. Tomita, Y. Uehara, S. S. Karnik, H. Yanagisawa, et al.
Molecular Mechanism Underlying Inverse Agonist of Angiotensin II Type 1 Receptor
J. Biol. Chem., July 14, 2006; 281(28): 19288 - 19295.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. E. Vanover, D. M. Weiner, M. Makhay, I. Veinbergs, L. R. Gardell, J. Lameh, A. L. Del Tredici, F. Piu, H. H. Schiffer, T. R. Ott, et al.
Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 910 - 918.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
E. Elisabetsky and L. Costa-Campos
The alkaloid alstonine: a review of its pharmacological properties.
Evid. Based Complement. Altern. Med., March 1, 2006; 3(1): 39 - 48.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
G. F. Elphick, W. Querbes, J. A. Jordan, G. V. Gee, S. Eash, K. Manley, A. Dugan, M. Stanifer, A. Bhatnagar, W. K. Kroeze, et al.
The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells
Science, November 19, 2004; 306(5700): 1380 - 1383.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. E. Vanover, S. C. Harvey, T. Son, S. R. Bradley, H. Kold, M. Makhay, I. Veinbergs, T. A. Spalding, D. M. Weiner, C. M. Andersson, et al.
Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 943 - 951.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
F. Paquet, J. P. Soucy, E. Stip, M. Levesque, A. Elie, and M. A. Bedard
Comparison Between Olanzapine and Haloperidol on Procedural Learning and the Relationship With Striatal D2 Receptor Occupancy in Schizophrenia
J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 47 - 56.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Kenakin
Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism
Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Milligan
Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective
Mol. Pharmacol., December 1, 2003; 64(6): 1271 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
E. Sanders-Bush, H. Fentress, and L. Hazelwood
Serotonin 5-HT2 Receptors: Molecular and Genomic Diversity
Mol. Interv., September 1, 2003; 3(6): 319 - 330.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. D. Stout, W. P. Clarke, and K. A. Berg
Rapid Desensitization of the Serotonin2C Receptor System: Effector Pathway and Agonist Dependence
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 957 - 962.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Rauser, J. E. Savage, H. Y. Meltzer, and B. L. Roth
Inverse Agonist Actions of Typical and Atypical Antipsychotic Drugs at the Human 5-Hydroxytryptamine2C Receptor
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 83 - 89.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. M. Weiner, E. S. Burstein, N. Nash, G. E. Croston, E. A. Currier, K. E. Vanover, S. C. Harvey, E. Donohue, H. C. Hansen, C. M. Andersson, et al.
5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 268 - 276.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. D. Price, D. M. Weiner, M. S. S. Chang, and E. Sanders-Bush
RNA Editing of the Human Serotonin 5-HT2C Receptor Alters Receptor-mediated Activation of G13 Protein
J. Biol. Chem., November 21, 2001; 276(48): 44663 - 44668.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.